UK Biobank Lifestyle Factors and CKM Syndrome Progression: 308,657 Participants

This dataset comprises 308,657 UK Biobank participants in CKM stages 0-3 at baseline, tracked for a median of 13.71 years to study lifestyle impacts on disease progression and mortality. It was created by Qi Chen using multi-state models and quantile G-computation to analyze transitions between clinical stages and death.

Use Cases

• Model transitions to CKM stage 4b using composite lifestyle scores and individual factors like smoking status.
• Quantify the relative contribution of never smoking (23.1-65.1%) to risk reduction across different stage transitions.
• Analyze hazard ratios for progression from baseline to stage 4b associated with lifestyle score groups (e.g., 0-1 vs. 5-6).
• Investigate the protective effect of lifestyle on the transition from stage 4a to death using reported hazard ratios.

Strengths

• Longitudinal data from 308,657 participants provides a substantial cohort for analysis.
• Median follow-up of 13.71 years enables long-term observation of CKM syndrome progression.
• Analysis includes refined clinical subtypes (stage 4a/4b) for more granular insights.

Limitations

• The underlying data is presented in a summarized PDF format (1.5 MB), limiting direct access to raw, row-level participant records.
• The study's geographic scope is limited to United Kingdom Biobank participants, which may not generalize to other populations.

Provenance

Source

United Kingdom Biobank.

Collection Method

Prospective cohort study using multi-state models and quantile G-computation.

Time Range

Median follow-up of 13.71 years.

Freshness

Last updated March 2026.

Geography

United Kingdom.